Ipsen’s Post

Catailyst Clinical Event Snippet: First Patient Enrolled/Dosed, Phase 2B MindBio Therapeutics Major Depressive Disorder Phase 2B Take-Home Microdosing (MB22001) Clinical Trial Follows successful Phase 2A trial where 53% of depressed patients were in complete remission from their depression at week 8 marked by a mean 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale), a 60% mean drop in depressive symptoms. #cns #biotech #depression #biopharma https://lnkd.in/eMddutyN

Catailyst Regulatory Event Snippets: Drug Approval in a Country Approval in China Shanghai Kechow Pharma, Inc. China National Medical Products Administration Approval of Tunlametinib (HL-085), the first approved targeted therapy NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 #melanoma a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study #Tunlametinib is a small molecule inhibitor of Mitogen-activated protein kinase kinase (MEK) 

Gaining a Deeper Purpose – a la Viatris Komárom Last year #Viatris launched an initiative called 'Gaining a Deeper Purpose' to encourage colleagues to find their deeper purpose in work: the things that make them tick, that urge them to be better every day and to contribute to our global mission - help millions of people to live healthier at every stage of life. This year, we, at Viatris Komárom, take this initiative forward and tailoring it to ourselves by launching the 'Gaining a Deeper Purpose - a la Viatris Komárom' campaign. Over the next two months, each function of our site will present itself in a way of its choosing: they will show what they do, what they want to achieve, what drives them every day – everything they contribute to our common success. As a prologue to this series of programs, today we've published a comic strip in which two agents try to uncover the secret of Viatris Komárom's success 😉. #Viatris #ViatrisKomarom #viaViatris #deeperpurose

See the difference with XcellerEYES™ - the lyophilized amniotic membrane that's bringing a new perspective in vision healthcare. Learn more about the unique benefits it can bring your practice today at https://lnkd.in/gBvyiXtM #eyecare #ophthalmology #amnioticgraft #lyophilization #oculusbiologics

#EPICis10: Quickfire Questions For our week reflecting on our American growth in our first decade, we quizzed some of our UK team on: 🤔 Why is the nature of this work so important in the US in particular? 🤔 What's been the most rewarding part of expanding into the US? #gambling #gamblingharm #harmprevention #problemgambling

Swing by to see our 2.0 platform

Catailyst, Inc. Trending Topics UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UroGen Pharma successfully completed the New Drug Application (NDA) submission for investigational drug UGN-102 (mitomycin) for intravesical solution. This marks a significant advancement in addressing the urgent need for innovative treatments for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGen is optimistic about potential FDA approval in early 2025, pending acceptance for filing and the granting of priority review. https://lnkd.in/eRbThV6F #Biotech #CancerResearch #FDAApproval

The new Cysteamine Isobionic-Amide complex from Cyspera® is changing the paradigm in hyperpigmentation. www.cyspera.com #hyperpigmentation

Push Your Boundaries, Shape Your Future with CliniPsy. As 2024 unfolds, CliniPsy stands by your side, guiding you to unlock your boundless potential. Embrace the journey of self-improvement and discovery with our expert support. We believe that everyone possesses an infinite reservoir of capabilities, just waiting to be tapped. Our unique approach helps you break through barriers, foster resilience, and realize your dreams. With CliniPsy, transform challenges into stepping stones and craft a future that exceeds your aspirations. Let 2024 be your year of breaking limits and achieving greatness with CliniPsy. #unlimitedpotential #CliniPsy #pushboundaries #shapeyourfuture #selfimprovement #discoveryourself #breakbarriers #achievegreatness #resiliencebuilding #transformchallenge

🎙 This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.